Oxaliplatin‑induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients

Abstract

Purpose: The aim of the current study is to report our prospective experience on the prevalence of oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients with digestive tract cancers treated with oxaliplatin-basedcombination therapy. Materials and Methods: A total of 219 patients scheduled to be treated with oxaliplatin-basedcombination therapy were prospectively examined at baseline and follow-up during the therapy between November 2014 and December 2016. The incidence of acute OXAIPN was measured using a descriptive questionnaire (yes/no question) based on sum of number of symptoms present and NCI-CTCAE version 4.03 was applied to clinically grade the severity of chronic OXAIPN. Results: Acute and chronic OXAIPN was found in 108 of 219 (49.3%) and 127 of 219 (58%) patients, respectively. Out of 11 acute OXAIPN symptoms, the vast majority of patients manifested cold-induced pharyngolaryngeal (63.8%) dysesthesias or perioral (61.1%) paresthesias. Development of acute OXAIPN was predictive of subsequent development of chronic OXAIPN (P = 0.0001). All the patients received a median cumulative dose of 780 mg/m2 (range: 130–1040 mg/m2). There was a significant correlation between the patients who received the median cumulative dose and the development of chronic OXAIPN. The incidences of OXAIPN in patients with median cumulative dose of ≤780 mg/m2 was 51/120 (42.5%) and >780 mg/m2 was OXAIPN 76/99 (76.7%) (P = 0.0001). Conclusion: The current study results demonstrate that the vast majority of patients who receive oxaliplatin-basedcombination chemotherapy will manifest acute OXAIPN that may contribute to the development of chronic peripheral neuropathy on repeated courses of drug administration.

Keywords

Digestive tract cancer - oxaliplatin - peripheral neuropathy - South Indian patients

Publication History

Article published online:
04 July 2021

• References

• 1 Hill EJ, Nicolay NH, Middleton MR, Sharma RA. Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: What have we learned from a decade of translational research? Crit Rev Oncol Hematol 2012;83:353-87.
• 2 André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
• 3 Pilancı KN, Saglam S, Okyar A, Yucel S, Pala-Kara Z, Ordu C, et al. Chronomodulated oxaliplatin plus capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II brunch regimen study. Cancer Chemother Pharmacol 2016;78:143-50.
• 4 Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-21.
• 5 Chao Y, Hsieh JS, Yeh HT, Su YC, Wu CC, Chen JS, et al. Amulticenter phase II study of biweekly capecitabine incombination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol 2014;73:799-806.
• 6 Wang Y, Zhuang RY, Yu YY, Yu S, Hou J, Ji Y, et al. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget 2016;7:76298-307.
• 7 Wang ZX, Yang XL, He MM, Wang F, Zhang DS, Li YH, et al. The efficacy of adjuvant FOLFOX6 for patients with gastric cancer after D2 lymphadenectomy: A Propensity score-matched analysis. Medicine (Baltimore) 2016;95:e3214.
• 8 Argyriou AA. Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics 2015;3:187-97.
• 9 Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33:15-49.
• 10 Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29:387-92.
• 11 McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;8:10-6.
• 12 Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin 2013;63:419-37.
• 13 Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 2014;22:1999-2007.
• 14 Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: A randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 2008;61:105-11.
• 15 Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, et al. Platinum-induced neurotoxicity and preventive strategies: Past, present, and future. Oncologist 2015;20:411-32.
• 16 Canta A, Pozzi E, Carozzi VA. Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics 2015;3:198-223.
• 17 Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005;5:116.
• 18 Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 2014;85:392-8.
• 19 Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer. Cancer 2013;119:438-44.
• 20 Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;30:5-13.
• 21 Storey DJ, Sakala M, McLean CM, Phillips HA, Dawson LK, Wall LR, et al. Capecitabinecombined with oxaliplatin (CapOx) in clinical practice: How significant is peripheral neuropathy? Ann Oncol 2010;21:1657-61.
• 22 Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in iran. Asian Pac J Cancer Prev 2015;16:7603-6.
• 23 Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M, et al. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011;77:980-6.
• 24 Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 2008;44:1507-15.
• 25 Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: Results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 2015;33:3416-22.
• 26 Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, et al. Peripheral neurotoxicity of oxaliplatin incombination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): A prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012;23:3116-22.
• 27 Baek KK, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: A prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010;42:185-90.
• 28 Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006;56:13-6.
• 29 Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC, et al. Long-term neuropathy after oxaliplatin treatment: Challenging the dictum of reversibility. Oncologist 2011;16:708-16.